» Articles » PMID: 33133061

The Anti-inflammatory Effects of HMGB1 Blockades in a Mouse Model of Cutaneous Vasculitis

Overview
Journal Front Immunol
Date 2020 Nov 2
PMID 33133061
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In our previous study, we have found increased serum levels of HMGB1 in patients with Henoch- Schonlein purpura (HSP), allergic vasculitis (AV), and urticarial vasculitis (UV) and altered HMGB1 distribution in lesional skin in patients with HSP. HMGB1 plays a pro-inflammatory role in the pathogenesis of HSP. To further investigate the role of HMGB1 in the pathogenic mechanism of vasculitis, we investigated the anti-inflammatory effects of HMGB1 blockades (including anti-HMGB1 mAb and glycyrrhizin) in a mouse model of a cutaneous reverse passive Arthus (RPA) reaction. A total of 36 balb/c mice were randomly divided into four groups: the control group, IC model group, HMGB1 monoclonal antibody (anti-HMGB1-mAb) group and the glycyrrhizin group, with nine mice in each group. A cutaneous RPA reaction mouse model was established by injections of the OVA antibody and the OVA antigen. Mice of the anti-HMGB1-mAb group and glycyrrhizin group were pre-treated with anti-HMGB1 mAb or glycyrrhizin, respectively, before the RPA reaction. Our results indicated that HMGB1 blockades (anti-HMGB1 mAb and glycyrrhizin) obviously extenuated the severity of vasculitis skin damage and improved the histological evolvement of inflammatory cells infiltration, vascular fibroid necrosis, and vasodilation in a cutaneous RPA reaction mouse model. In addition, HMGB1 blockades reduced the infiltration of neutrophils, DCs, and T cells and decreased the mRNA expression of IL-6 and CCL5 in skin lesions in the cutaneous RPA reaction mouse model. We suggest that HMGB1 blockades may represent a new direction for the treatment of cutaneous vasculitis.

Citing Articles

Role of HMGB1 in Vitiligo: Current Perceptions and Future Perspectives.

Wei G, Pan Y, Wang J, Xiong X, He Y, Xu J Clin Cosmet Investig Dermatol. 2022; 15:2177-2186.

PMID: 36267690 PMC: 9576603. DOI: 10.2147/CCID.S381432.


HMGB-1 in Psoriasis.

Casciaro M, Di Salvo E, Gangemi S Biomolecules. 2022; 12(1).

PMID: 35053208 PMC: 8774071. DOI: 10.3390/biom12010060.


Epigenetic Regulator KDM4D Restricts Tumorigenesis Modulating SYVN1/HMGB1 Ubiquitination Axis in Esophageal Squamous Cell Carcinoma.

Yao W, Wang J, Zhu L, Jia X, Xu L, Tian X Front Oncol. 2021; 11:761346.

PMID: 34820329 PMC: 8606580. DOI: 10.3389/fonc.2021.761346.


Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma.

Kam N, Wu K, Dai W, Wang Y, Yan L, Shakya R Angiogenesis. 2021; 25(2):181-203.

PMID: 34617194 PMC: 8494172. DOI: 10.1007/s10456-021-09819-0.


The Immune Tolerance Role of the HMGB1-RAGE Axis.

Watanabe H, Son M Cells. 2021; 10(3).

PMID: 33807604 PMC: 8001022. DOI: 10.3390/cells10030564.

References
1.
Klune J, Dhupar R, Cardinal J, Billiar T, Tsung A . HMGB1: endogenous danger signaling. Mol Med. 2008; 14(7-8):476-84. PMC: 2323334. DOI: 10.2119/2008-00034.Klune. View

2.
Andersson U, Wang H, Palmblad K, Aveberger A, Bloom O, Erlandsson-Harris H . High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000; 192(4):565-70. PMC: 2193240. DOI: 10.1084/jem.192.4.565. View

3.
Carlson J . The histological assessment of cutaneous vasculitis. Histopathology. 2010; 56(1):3-23. DOI: 10.1111/j.1365-2559.2009.03443.x. View

4.
Lee C, Park S, Kim Y, Kang S, Kim J, Lee S . Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice. Biol Pharm Bull. 2007; 30(10):1898-904. DOI: 10.1248/bpb.30.1898. View

5.
Ming L, Yin A . Therapeutic effects of glycyrrhizic acid. Nat Prod Commun. 2013; 8(3):415-8. View